Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real‐World Evidence Approach
ABSTRACT Purpose Clinical trials (CTs) are essential for the research and development of new cancer treatment technologies. Evaluating their economic impact and the potential cost savings for healthcare systems in low‐ and middle‐income countries is crucial for informing healthcare policy and decisi...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.71099 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331458330591232 |
|---|---|
| author | Leonardo Rojas Natalia Sánchez Jorge Ceballos Antonio Robles Carlos A. Badillo Virginia Abello Carlos Bonilla William A. Mantilla Jairo Zuluaga Gilberto Lopes Oscar Arrieta Andrés F. Cardona |
| author_facet | Leonardo Rojas Natalia Sánchez Jorge Ceballos Antonio Robles Carlos A. Badillo Virginia Abello Carlos Bonilla William A. Mantilla Jairo Zuluaga Gilberto Lopes Oscar Arrieta Andrés F. Cardona |
| author_sort | Leonardo Rojas |
| collection | DOAJ |
| description | ABSTRACT Purpose Clinical trials (CTs) are essential for the research and development of new cancer treatment technologies. Evaluating their economic impact and the potential cost savings for healthcare systems in low‐ and middle‐income countries is crucial for informing healthcare policy and decision‐making. This study estimates the economic benefits to the Colombian healthcare system from the inclusion of hematology and oncology patients in sponsored CTs. Methods This study utilized real‐world data from the Luis Carlos Sarmiento Angulo Cancer Treatment and Research Centre (CTIC), a comprehensive cancer center in Bogotá, Colombia. Tumor types were selected based on their prevalence and economic burden. A Budget Impact Analysis was conducted following the methodology of the local Health Technology Assessment Agency, using data from five prioritized tumor types. Clinical data and associated costs were extracted from the institutional data lake, and cost‐generating events for each disease were validated by CTIC clinical experts. The estimated eligible population for phase 3 CTs was derived from literature reviews and expert opinions from CTIC clinicians. Prevalent and incident population data were obtained from the Colombian High‐Cost Account. Results A total of 7703 potential patients were eligible for inclusion in the CTs, with an associated healthcare cost of USD 244,151,552 by 2023 (1 USD = 4325 COP). If at least 20% of these patients participated in CTs by 2023, the projected annual cost savings would be USD 48,830,310. Among the evaluated cancers, advanced prostate cancer incurred the highest costs due to its high prevalence and potential for inclusion in CTs. Conclusion Over 5 years, potential cost savings could range from USD 244 million (assuming a 20% enrolment rate) to 1.22 billion (with 100% enrolment), alleviating financial pressures on the Colombian healthcare system. These savings would contribute to the system's long‐term financial sustainability while ensuring timely access to innovative cancer treatments. |
| format | Article |
| id | doaj-art-347741b77beb4676bcb628776fc78e0e |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-347741b77beb4676bcb628776fc78e0e2025-08-20T03:46:34ZengWileyCancer Medicine2045-76342025-08-011415n/an/a10.1002/cam4.71099Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real‐World Evidence ApproachLeonardo Rojas0Natalia Sánchez1Jorge Ceballos2Antonio Robles3Carlos A. Badillo4Virginia Abello5Carlos Bonilla6William A. Mantilla7Jairo Zuluaga8Gilberto Lopes9Oscar Arrieta10Andrés F. Cardona11Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC) Bogotá ColombiaLuis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC) Bogotá ColombiaLuis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC) Bogotá ColombiaRoche Colombia Bogotá ColombiaRoche Colombia Bogotá ColombiaLuis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC) Bogotá ColombiaLuis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC) Bogotá ColombiaLuis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC) Bogotá ColombiaLuis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC) Bogotá ColombiaDivision of Medical Oncology Associate Director for the Cancer Center and Medical Director for International Affairs, Sylvester Comprehensive Cancer Center Miami Florida USAThoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan) Mexico City MexicoLuis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC) Bogotá ColombiaABSTRACT Purpose Clinical trials (CTs) are essential for the research and development of new cancer treatment technologies. Evaluating their economic impact and the potential cost savings for healthcare systems in low‐ and middle‐income countries is crucial for informing healthcare policy and decision‐making. This study estimates the economic benefits to the Colombian healthcare system from the inclusion of hematology and oncology patients in sponsored CTs. Methods This study utilized real‐world data from the Luis Carlos Sarmiento Angulo Cancer Treatment and Research Centre (CTIC), a comprehensive cancer center in Bogotá, Colombia. Tumor types were selected based on their prevalence and economic burden. A Budget Impact Analysis was conducted following the methodology of the local Health Technology Assessment Agency, using data from five prioritized tumor types. Clinical data and associated costs were extracted from the institutional data lake, and cost‐generating events for each disease were validated by CTIC clinical experts. The estimated eligible population for phase 3 CTs was derived from literature reviews and expert opinions from CTIC clinicians. Prevalent and incident population data were obtained from the Colombian High‐Cost Account. Results A total of 7703 potential patients were eligible for inclusion in the CTs, with an associated healthcare cost of USD 244,151,552 by 2023 (1 USD = 4325 COP). If at least 20% of these patients participated in CTs by 2023, the projected annual cost savings would be USD 48,830,310. Among the evaluated cancers, advanced prostate cancer incurred the highest costs due to its high prevalence and potential for inclusion in CTs. Conclusion Over 5 years, potential cost savings could range from USD 244 million (assuming a 20% enrolment rate) to 1.22 billion (with 100% enrolment), alleviating financial pressures on the Colombian healthcare system. These savings would contribute to the system's long‐term financial sustainability while ensuring timely access to innovative cancer treatments.https://doi.org/10.1002/cam4.71099cancer treatmentclinical trialseconomic impacthealthcare efficiency |
| spellingShingle | Leonardo Rojas Natalia Sánchez Jorge Ceballos Antonio Robles Carlos A. Badillo Virginia Abello Carlos Bonilla William A. Mantilla Jairo Zuluaga Gilberto Lopes Oscar Arrieta Andrés F. Cardona Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real‐World Evidence Approach Cancer Medicine cancer treatment clinical trials economic impact healthcare efficiency |
| title | Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real‐World Evidence Approach |
| title_full | Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real‐World Evidence Approach |
| title_fullStr | Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real‐World Evidence Approach |
| title_full_unstemmed | Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real‐World Evidence Approach |
| title_short | Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real‐World Evidence Approach |
| title_sort | economic benefits of sponsored clinical trials in cancer for the colombian healthcare system a real world evidence approach |
| topic | cancer treatment clinical trials economic impact healthcare efficiency |
| url | https://doi.org/10.1002/cam4.71099 |
| work_keys_str_mv | AT leonardorojas economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach AT nataliasanchez economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach AT jorgeceballos economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach AT antoniorobles economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach AT carlosabadillo economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach AT virginiaabello economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach AT carlosbonilla economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach AT williamamantilla economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach AT jairozuluaga economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach AT gilbertolopes economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach AT oscararrieta economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach AT andresfcardona economicbenefitsofsponsoredclinicaltrialsincancerforthecolombianhealthcaresystemarealworldevidenceapproach |